Objective: Previous studies have estimated future PD prevalence based on population aging. This study revisits that projection by accounting for the potential impact of declining rates of smoking.
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Dorsey and colleagues 10 estimated the prevalence of PD in the year 2005 in 15 countries (including the United States) according to age group. The study projected PD prevalence for the year 2030 and has become a landmark for estimates of future economic and social burdens of PD. However, it projected PD prevalence based only on the aging of the population, not taking into account the trend toward the decline of smoking that suggests that the decline of smoking will contribute to a higher PD incidence in the years to come. Thus we have included the predicted smoking trend in reexamining the previous projection of PD prevalence to provide a more accurate estimate of the future prevalence.
Methods
Data on both historical and projected U.S. populations by gender from the years 1990 to 2040 were obtained from the U.S. Census Bureau. 3 The data were tabulated based on age-and gender-specific cohorts of ages 50-64, 65-74, and 751 for each calendar year.
Data regarding historical and future estimates of smoking prevalence from 1990 to the year 2040 were obtained from the Surgeon General's Report on smoking, 11 specifically projections by Holford and colleagues. 12 The prevalence rates for current, former, and nonsmokers were derived for age-and genderspecific cohorts of ages 50-64, 65-74, and 751 for each calendar year.
In PD, dopamine cell loss may start 5 to 13 years or more before clinical diagnosis. 13, 14 Thus we implemented a 10-year lag of smoking behavior to predict PD prevalence in a given year to account for the temporal effect of smoking on PD incidence.
A large meta-analysis including 44 case-control studies and 4 cohort studies determined a pooled relative risk of PD of 0.59 for former smokers and a relative risk of 0.39 for current smokers. 9 The largest study in the United States with detailed smoking data determined odds ratios of 0.56 for current and 0.78 for former smokers. 15 Because the incidence of PD is so low in the general population, the odds ratio can reasonably be interpreted as relative risk. 16 The model incorporates odds ratios for PD of 0.78 for former smokers and 0.56 for current smokers; this represents the more conservative U.S. estimates. 15, 17 We applied the population data to PD prevalence models, where P is prevalence and Pop is population. First, we used the same prevalence estimates from Dorsey and colleagues 10 for each age cohort (P 50-64 , P 65-74 , P 751 ) to calculate the PD prevalence in each year until the year 2040 equation (1) . This model does not account for smoking. 
Then we projected PD prevalence until the year 2040 by accounting for smoking prevalence. The overall prevalence of PD for a given year resulted from a summation of the output of the following model for each age-gender cohort equation (2): 
Results
From year 2000 to 2040, the U.S. population !50 years of age will increase by 46.2% while the percentage of smokers !50 years of age will decrease by 59.8% (Fig. 1) . The absolute number of former smokers in the United States will plateau, although the percentage of the population comprised by this group will decrease. By the year 2040, active smokers are expected to be only 3.5% of the U.S. population !50 years of age, whereas former smokers are predicted to be 26.4%.
The number of people in the United States with PD in the year 2040 is projected equation (1) to be approximately 700,000 individuals due to aging alone (Fig. 2) . This number, however, will increase to approximately 770,000 (10% higher) if smoking truly decreases PD risk and the current trend toward decreased smoking continues equation (2) . This represents an approximately 56% increase in the PD population between 2005 and 2040. Our model also demonstrates an overall disease prevalence rate of 0.535% of the entire U.S. population in 2040 compared with a prevalence rate of 0.401% in the year 2005. As shown in Figures 1 and 2 , the burden of PD in the United States will grow substantially as the prevalence of smoking continues to decrease. The divergence between PD prevalence projections ( Fig. 2) occurs because the prevalence of smoking in the United States is expected to continue to decrease. 10 Of note, the U.S. Surgeon General's projected changes in smoking habits within the U.S. population and population growth are nonlinear, resulting in the nonmonophasic increase in cases of PD and the initial crossover of the models shown in Figure 2 . Although the proportion of smokers in the overall population is expected to decrease over time, certain age cohorts are projected to experience increases in the number of smokers at various time points rather than a continual decrease. The divergence of the PD prevalence projections occurs farther in the future when the number of smokers across all cohorts is decreased in contrast to decreases only in certain age cohorts earlier in time. 12 
Discussion
Chronic diseases constitute a major health care burden in the United States. 18 Estimates of annual disease-related medical costs per PD patient range from $10,378 to $14,400 (in 2010 U.S. dollars), not including indirect costs. [19] [20] [21] [22] Our study suggests that previous projections may have underestimated PD prevalence by 10% in the coming decade by not accounting for the impact of decreasing rates of smoking. Even by our conservative estimates, these 70,000 additional PD cases would add an annual cost of greater than $700 million for the United States.
Estimates of PD prevalence vary widely, although there is a lack of current large studies for the United States. 23 A commonly cited estimate of U.S. prevalence of PD based on a single door-to-door survey was extrapolated to an estimated PD prevalence of 430,000 in 2010 for the population aged older than 40. 24 Recently, Strickland and Bertoni 25 used a PD registry combined with capture-recapture methodology in Nebraska in 2000 and estimated a 2010 PD prevalence estimate for people aged 40 or older of nearly 920,000 individuals in the United States, somewhat greater than Kowal and colleagues 19 whose estimate was 630,000 people. Other studies also have focused on estimated incidence of PD. [26] [27] [28] [29] [30] The most conservative estimates have generally used door-todoor surveys or autopsy data, whereas studies that focus on claims data yielded higher estimates. 30 In the current study, we selected the conservative, well-accepted, and widely cited estimate of PD prevalence from Dorsey and colleagues 10 as our base model. They used International Data Base's population pyramids in combination with door-to-door studies with age-specific prevalence to create a model that estimated 373,968 individuals in 2010. 10 Our model also used conservative modifiers for the effect of former and current smoking on the risk of developing PD. Other studies report risk reductions as profound as 74% in current smokers. 31 Therefore, it stands to reason that our estimate of disease prevalence for the year 2040 is also conservative and in reality the number may be much greater.
The results indicate that if tobacco nonuse is indeed causally related to an increased risk of PD, past projections may underestimate the prevalence of PD in 2040 by at least 10%. The PD prevalence that our model projects would vary based on the source data for current PD prevalence, but we emphasize that accounting for declining rates of smoking, regardless of baseline disease prevalence, is necessary for a more accurate depiction of future PD burden. This also holds true for the degree of risk modification due to smoking that is used in the model, which also varies in the literature. 9, 15 A recent study by Savica and colleagues 32 demonstrated that the incidence of PD might have increased during the 30-year time period from 1976 to 2005. Although intriguing, this finding needs confirmation, as one may speculate that it may be due, at least to some extent, to the decreasing trend of smoking in the past 50 years in the United States.
32 Therefore, our model incorporating the diminishing trend in smoking may offer a more accurate projection of future PD prevalence if smoking is indeed causally linked to PD risk. Smoking prevalence is projected to continue to decline with ongoing nationwide smoking cessation health initiatives. 12 The Centers for Disease Control has set a goal of decreasing smoking prevalence to 12% of the population by the year of 2020. 33 Until smoking prevalence reaches its nadir, it is reasonable to expect continual increases in yearly PD incidence with a plateau beginning in 2030 and with subsequent effects on disease prevalence.
Our model relies on the hypothesis that smoking is neuroprotective for PD, thus PD prevalence will decrease as smoking decreases in the United States. It has been proposed, however, that this effect is the result of decreased responsiveness to nicotine in the PD prodromal period, thereby leading to decreased rates of smoking in individuals later diagnosed with PD. 34 Although this latter idea is not widely accepted, if true it would nullify the current calculations. This limitation is important, as causality has not been proven. We also used a 10-year lag in estimating the influence of smoking on PD risk, but we recognize that this is somewhat arbitrary and also limits the accuracy of our projections. Finally, projection accuracy is predicated on the estimates of future numbers of smokers, former smokers, and nonsmokers; this is dependent on the continued success of public health measures related to smoking cessation.
Above and beyond medical costs, as a chronic condition, PD imposes a significant burden on families and caregivers that is not easily quantified. This will continue to grow as the size of the elderly population in the United States continues to increase. Our study suggests additional resources are likely to be needed above those currently estimated.
